Table 1 Characteristics of the 1610 participants in the study among the 12 sentinel ART sites in Zimbabwe between 2008 and 2010
Characteristic | N (%) |
|---|---|
Gender | |
Female | 1106 (68.7) |
Male | 487 (30.3) |
Missing data | 17 (1.1) |
Age | |
Median age (IQR) | 36 (30;44) |
WHO clinical staging | |
Stage 1 | 106 (6.6) |
Stage 2 | 289 (18.0) |
Stage 3 | 951 (59.1) |
Stage 4 | 78 (4.8) |
Missing data | 186 (11.5) |
Previous Antiretroviral drugs (ARVs) exposure | |
PMTCT | 63 (3.9) |
ARVs prior to initiation | 18 (1.1) |
Others | 6 (0.4) |
No exposure | 1139 (70.7) |
Missing exposure status | 384 (23.9) |
CD4 count | |
Median baseline CD4 count (IQR) | 168 (94;253) |
Females | 180 (106;265) |
Males | 136 (71;222) |
Viral loads (copies/ml) | |
≥1000 | 1417 (95.67) |
Females | 982 (66.31) |
Males | 435 (29.36) |
<1000 | 46 (4.33) |
Drug resistance mutations | |
No. with genotyping results | 1483 |
No resistance | 1389 |
NNRTI resistance only | 73 (4.9) |
NRTI resistance only | 18 (1.2) |
NRTI + NNRTI resistance | 5 (0.3) |
PI resistance | 10 (0.7) |
Any resistance mutation | 94 (6.3) |